About-cancer/treatment/clinical-trials/disease/melanoma/treatment

Gwajin Gwajin Clinical don Melanoma

Gwajin gwaji shine karatun bincike wanda ya shafi mutane. Gwajin gwaji a wannan jerin don maganin melanoma ne. Duk gwaji akan jerin suna samun tallafi daga NCI.

Babban bayanin NCI game da gwajin asibiti yayi bayanin nau'ikan da matakan gwajin da yadda ake aiwatar dasu. Gwajin gwaji na duba sabbin hanyoyin kariya, ganowa, ko magance cuta. Kuna so kuyi tunani game da shiga cikin gwajin gwaji. Yi magana da likitanka don taimako yayin yanke shawara idan ɗaya ya dace maka.

Gwaji 1-25 na 260 1 2 3 ... 11 Na gaba>

Maganin da aka Yi niyya wanda Gudanar da Kwayoyin Halitta ke jagoranta don Kula da Marasa lafiya tare da Ciwon Raunin Tumbi mai Girma, Lymphomas, ko Myeloma Mai Yawa (The MATCH Tantance Trial)

Wannan lokaci na II MATCH fitina yayi nazari game da yadda maganin da ake gwada shi ta hanyar gwajin kwayar halitta ke aiki a marasa lafiya da keɓaɓɓen ciwan ciki ko ƙwayoyin cuta waɗanda suka ci gaba bayan bin aƙalla layi ɗaya na daidaitaccen magani ko kuma wanda ba a yarda da tsarin magani ba. Gwajin kwayoyin halitta suna kallon keɓaɓɓiyar kwayar halitta (kwayoyin halitta) na ƙwayoyin ƙari na marasa lafiya. Marasa lafiya da ke fama da cututtukan kwayoyin halitta (kamar maye gurbi, karin haske, ko sauyawa) na iya fa'idantar da ƙarin magani wanda ke sa ido game da cututtukan ƙwayoyin cuta na yau da kullun. Gano waɗannan cututtukan cututtukan ƙwayoyin cuta na farko na iya taimaka wa likitoci su shirya kyakkyawan magani ga marasa lafiya da keɓaɓɓen ciwace-ciwacen ƙwaya, lymphomas, ko myeloma mai yawa.

Wuri: wurare 1189

Pembrolizumab a Kula da Marasa lafiya tare da Mataki na III-IV Babban haɗarin Melanoma Kafin da Bayan Tiyata

Wannan gwaji na zamani na II yana nazarin yadda pembrolizumab ke aiki kafin da bayan tiyata wajen kula da marasa lafiya tare da matakin melanoma mai haɗari na III-IV. Immunotherapy tare da kwayoyin cuta na monoclonal, kamar pembrolizumab, na iya taimaka wa garkuwar jiki ta kai hari ga kansar, kuma yana iya tsoma baki tare da ikon ƙwayoyin ƙari don girma da yaɗuwa. Ba da pembrolizumab kafin da bayan tiyata na iya aiki mafi kyau wajen magance melanoma.

Wuri: wurare 709

Dabrafenib da Trametinib Biye da Ipilimumab da Nivolumab ko Ipilimumab da Nivolumab Biye da Dabrafenib da Trametinib a Kula da Marasa lafiya da Mataki na III-IV BRAFV600 Melanoma

Wannan gwajin gwagwarmaya na zamani yayi nazarin yadda maganin farko tare da ipilimumab da nivolumab suka biyo bayan dabrafenib da trametinib ke aiki kuma yayi kwatancen shi da magani na farko tare da dabrafenib da trametinib sai kuma ipilimumab da nivolumab wajen kula da marasa lafiya da mataki na III-IV melanoma wanda ya ƙunshi maye gurbi da aka sani da BRAFV600 kuma ba za a iya cire shi ta hanyar tiyata ba (ba za a iya cire shi ba). Immunotherapy tare da kwayoyin cuta na monoclonal, kamar ipilimumab da nivolumab, na iya taimakawa tsarin garkuwar jiki ya kai hari kansar, kuma yana iya tsoma baki tare da ikon ƙwayoyin ƙwayoyin cuta su girma da yaɗuwa. Dabrafenib da trametinib na iya toshe haɓakar tumo ta hanyar niyyar jigilar BRAFV600.

Wuri: Wurare 712

Ipilimumab tare da ko ba tare da Nivolumab ba a Kula da Marasa lafiya tare da Melanoma Wannan Matsayi ne na IV ko Mataki na III kuma Ba za a Iya Cire shi ta Tiyata

Wannan gwajin na II yana nazarin yadda ipilimumab yayi aiki tare ko ba tare da nivolumab ba wajen kula da marasa lafiya tare da melanoma wanda shine mataki na IV ko mataki na III kuma baza'a iya cire shi ta hanyar tiyata ba. Immunotherapy tare da kwayoyin cuta na monoclonal, kamar ipilimumab da nivolumab, na iya taimakawa tsarin garkuwar jiki ya kai hari kansar, kuma yana iya tsoma baki tare da ikon ƙwayoyin tumo don girma da yaɗuwa.

Wuri: wurare 600

Pembrolizumab a Kula da Marasa lafiya tare da Melanoma mai ɓarna wanda ba za a iya cire shi ta hanyar tiyata ba

Wannan gwajin gwajin lokaci na II yayi nazarin yadda pembrolizumab ke aiki sosai wajan kula da marasa lafiya tare da melanoma mai lalacewa (DM) wanda zai iya ko ba za'a cire shi ta hanyar tiyata ba (ba za'a iya tantancewa ba). Kwayoyin cuta na Monoclonal, kamar pembrolizumab, na iya toshe takamaiman sunadarai wanda zai iya ƙarfafa garkuwar jiki da kuma kula da ci gaban ƙari.

Wuri: Wurare 202

Nazarin Kwandon kwando na Entrectinib (RXDX-101) don Kula da Marasa Lafiya Tare da Tarfafa Ciwon Tumor NTRK 1/2/3 (Trk A / B / C), ROS1, ko ALK Gene Rearrangements (Fusions)

Wannan sigar buɗe-lakabi ce, mai yawa-yawa, nazarin kwandon duniya na 2 na entrectinib (RXDX-101) don kula da marasa lafiya tare da ciwace-ciwacen da ke ɗauke da NTRK1 / 2/3, ROS1, ko kuma haɗin ALK. Za a sanya marasa lafiya zuwa kwanduna daban-daban bisa ga nau'in tumo da haɗakar jiji.

Wuri: wurare 26

Tsaro da Ingancin Pembrolizumab Idan aka kwatanta da Placebo a cikin Mataki mai haɗarin Mataki na II Melanoma (MK-3475-716 / KEYNOTE-716)

Wannan nazarin na 2 zai kimanta aminci da inganci na pembrolizumab (MK-3475) idan aka kwatanta da placebo a cikin mahalarta tare da sake tiyata da aka yi haɗarin Mataki na II melanoma. Mahalarta a Sashe na 1 zasu karɓi pembrolizumab ko placebo a cikin zane mai makafi biyu har zuwa zagaye 17. Mahalarta waɗanda suka karɓi placebo ko waɗanda suka dakatar da magani bayan karɓar zagaye na 17 na pembrolizumab a Sashe na 1, ba sa fuskantar sake dawowar cuta a cikin watanni 6 da kammala pembrolizumab a Sashe na 1, kuma ba sa dakatar da jiyya tare da pembrolizumab don sake cutar ko rashin haƙuri, na iya cancanci karɓa har zuwa 35 ƙarin hawan keke na pembrolizumab a cikin Sashe na 2 a cikin zane mai buɗewa. Babban ra'ayi na wannan binciken shine cewa pembrolizumab yana ƙaruwa da sake dawowa ba tare da sake dawowa ba (RFS) idan aka kwatanta da placebo.

Wuri: Wurare 25

Nivolumab tare da ko ba tare da Ipilimumab a Kula da Matasa Marasa lafiya tare da Maimaitawa ko orarfin Twayar Tumor ko Sarcomas

Wannan gwaji na I / II yana nazarin illolin illa da mafi kyawun kwayar cutar nivolumab lokacin da aka basu tare da ko ba tare da ipilimumab ba don ganin yadda suke aiki wajen kula da ƙananan marasa lafiya tare da ciwace-ciwacen ƙwayoyi masu ƙarfi ko sarcomas waɗanda suka dawo (maimaitawa) ko ba sa amsa magani ( mai hanawa) Immunotherapy tare da kwayoyin cuta na monoclonal, irin su nivolumab da ipilimumab, na iya taimakawa tsarin garkuwar jiki ya kai hari kansar, kuma yana iya tsoma baki tare da ikon ƙwayoyin tumo don girma da yaɗuwa. Har yanzu ba a sani ba ko nivolumab yana aiki mafi kyau shi kaɗai ko tare da ipilimumab wajen kula da marasa lafiya tare da mawuyacin ciwace-ciwacen ƙwayoyi ko sarcomas.

Wuri: Wurare 24

Nazarin Haɓakawa da Expaddamar da Studyungiyar Nazarin NKTR-214 a cikin Haɗuwa Tare da Nivolumab da Sauran Magungunan Magungunan Cutar Cancer a Marasa lafiya Tare da Zaɓi Solananan Tumor masu Inganci (PIVOT-02)

A cikin wannan binciken mai sassa hudu, za a gudanar da NKTR-214 a hade tare da nivolumab a Sashe na 1, a hade tare da nivolumab tare da ko ba tare da magunguna da yawa a Sashi na 2, kuma tare da nivolumab da ipilimumab a Sashe na 3 & 4. A Sashe na 1, da An ba da Shawarwarin Kashi na 2 (RP2D) na NKTR-214 a hade tare da nivolumab. A Sashe na 2, NKTR-214 tare da nivolumab a cikin RP2D za a kimanta azaman maganin layin farko da / ko azaman biyun layin na uku ko na uku a zaɓar marasa lafiya tare da Melanoma, Renal Cell Carcinoma (RCC), Nonananan Laramar Lwayar Cutar (NSCLC ), Urothelial Carcinoma (UC), Ciwon daji na ƙwayar cuta (mBC) da Cancer na Colorectal (CRC). Bugu da ƙari, a cikin Sashe na 2, za a ƙaddara RP2D na NKTR-214 tare da nivolumab da magunguna da magunguna masu yawa a cikin zaɓaɓɓu na ƙungiyar masu haƙuri na NSCLC. A Sashe na 3, da dama daban-daban na tsarin sau uku na NKTR-214 da nivolumab da ipilimumab za a kimanta su a cikin zaɓaɓɓun marasa lafiya tare da RCC, NSCLC, Melanoma, da UC. A Sashe na 4, za a ƙara nazarin aminci da inganci na haɗin haɗin sau uku a cikin zaɓaɓɓun marasa lafiya tare da RCC, NSCLC, Melanoma da UC.

Wuri: wurare 22

Karatun 1 / 1b na Lokaci don Tattauna da Tsaro da Haƙuri na CPI-444 Shi kaɗai kuma a Haɗa Tare da Atezolizumab a Ciwon Cancers

Wannan sigar bude-lakabin 1 / 1b ne, mai magana da yawa, nazarin zabin kashi-kashi na CPI-444, karamin kwayar kwayar baka wacce take niyya ga mai karbar adenosine-A2A akan T-lymphocytes da sauran kwayoyin halittar garkuwar jiki. Wannan gwajin zaiyi nazarin aminci, jurewa, da aikin hana kumburi na CPI-444 a matsayin wakili guda ɗaya kuma a haɗe tare da atezolizumab, mai hana PD-L1 akan ƙwayoyi masu ƙarfi. CPI-444 yana toshe adenosine daga ɗaure ga mai karɓar A2A. Adenosine yana hana aikin anti-ƙari na ƙwayoyin T da sauran ƙwayoyin cuta.

Wuri: wurare 22

Nazarin Pembrolizumab (MK-3475) a cikin Mahalarta Ilimin Yara tare da Ciwon Tumor mai Girma ko Lymphoma (MK-3475-051 / KEYNOTE-051)

Wannan bincike ne kashi biyu na pembrolizumab (MK-3475) a cikin mahalarta likitan yara waɗanda ke da ɗayan nau'ikan nau'ikan cutar kansa: - ci gaban melanoma (watanni 6 zuwa shekaru 18), - ci gaba, koma baya ko ƙaddarar mutuwa - ligand 1 (PD-L1) - mai cutar kansa mai girma ko wasu ƙwayoyin lymphoma (watanni 6 zuwa <18 shekara), - koma baya ko ƙyamar aji Hodgkin lymphoma (rrcHL) (shekaru 3 zuwa <18 shekara), ko - ci gaba sake komowa ko kuma raunin microsatellite-rashin kwanciyar hankali-mai ƙarfi (MSI-H) mai kumburi mai ƙarfi (watanni 6 zuwa <18 shekara). Sashe na 1 zai sami iyakar haƙuri (MTD) / matsakaicin sarrafawa (MAD), ya tabbatar da sashi, kuma ya sami shawarar kashi na 2 na biyu (RP2D) don maganin pembrolizumab. Sashe na 2 zai kara kimanta aminci da inganci a cikin yara RP2D. Maganar farko ta wannan binciken ita ce, maganin cikin jini (IV) na pembrolizumab ga yara tare da ko dai ci gaban melanoma; wani PD-L1 tabbatacce mai ci gaba, ya sake komawa baya ko ƙari mai ƙyama ko wani ƙwayar lymphoma; ci-gaba, koma baya ko naƙasasshe MSI-H mai ƙarfi mai kumburi; ko rrcHL, zai haifar da Respimar Amsar Amfani (ORR) mafi girma fiye da 10% don aƙalla ɗayan waɗannan nau'o'in ciwon daji. Tare da Kwaskwarimar 8, an rufe rajistar mahalarta tare da ciwan ciwuka da na mahalarta masu shekaru 6 zuwa <12 years with melanoma. Rijistar mahalarta shekaru ≥12 zuwa ≤18 shekaru tare da melanoma ya ci gaba. Har ila yau, yin rajistar mahalarta tare da ciwace-ciwacen ƙwayoyin cuta na MSI-H. koma baya ko nakasa MSI-H daskararren ƙari; ko rrcHL, zai haifar da Respimar Amsar Amfani (ORR) mafi girma fiye da 10% don aƙalla ɗayan waɗannan nau'o'in ciwon daji. Tare da Kwaskwarimar 8, an rufe rajistar mahalarta tare da ciwan ciwuka da na mahalarta masu shekaru 6 zuwa <12 years with melanoma. Rijistar mahalarta shekaru ≥12 zuwa ≤18 shekaru tare da melanoma ya ci gaba. Har ila yau, yin rajistar mahalarta tare da ciwace-ciwacen ƙwayoyin cuta na MSI-H. koma baya ko nakasa MSI-H daskararren ƙari; ko rrcHL, zai haifar da Respimar Amsar Amfani (ORR) mafi girma fiye da 10% don aƙalla ɗayan waɗannan nau'o'in ciwon daji. Tare da Kwaskwarimar 8, an rufe rajistar mahalarta tare da ciwan ciwuka da na mahalarta masu shekaru 6 zuwa <12 years with melanoma. Rijistar mahalarta shekaru ≥12 zuwa ≤18 shekaru tare da melanoma ya ci gaba. Har ila yau, yin rajistar mahalarta tare da ciwace-ciwacen ƙwayoyin cuta na MSI-H.

Wuri: wurare 19

Tsaro da Inganci na IMCgp100 Akan Zaɓin Mai Binciken a Ci gaban Uveal Melanoma

Don kimanta rayuwar HLA-A * 0201 tabbatacciya marasa lafiya tare da ci gaban UM wanda ba a taɓa magance shi ba wanda ke karɓar IMCgp100 idan aka kwatanta da Zaɓin mai binciken dacarbazine, ipilimumab, ko pembrolizumab.

Wuri: wurare 18

Enapotamab Vedotin (HuMax-AXL-ADC) Nazarin Tsaro a cikin Marasa lafiya Tare da Ciwan Tumur

Dalilin fitinar shine a tantance matsakaicin matakin da za'a iya jurewa da kuma tabbatar da martabar lafiyar HuMax-AXL-ADC a cikin cakudadden yawan marasa lafiya tare da keɓaɓɓiyar ƙwayar cuta

Wuri: wurare 18

Nazarin XmAb®20717 a cikin Batutuwa Tare da Zaɓaɓɓun Twararrun umwayoyi

Wannan na 1 ne na zamani, kashi dayawa, yawan kara hauhawar bincike don bayyana MTD / RD da tsarin XmAb20717, don bayyana aminci da juriya, don tantance PK da rigakafin cuta, kuma don tantance aikin hana tumor na XmAb20717 a cikin batutuwa tare da zaɓaɓɓu ci gaba m marurai.

Wuri: Wurare 15

Talimogene Laherparepvec da Pembrolizumab a Kula da Marasa Lafiya tare da Mataki na III-IV Melanoma

Wannan gwajin na lokaci na II yana nazarin yadda talimogene laherparepvec da pembrolizumab ke aiki wajen kula da marasa lafiya da matakin III-IV melanoma. Magungunan ilimin halittu, kamar talimogene laherparepvec, suna amfani da abubuwan da aka ƙera daga ƙwayoyin rai waɗanda zasu iya haɓaka ko kuma hana tsarin garkuwar jiki ta hanyoyi daban-daban kuma dakatar da ƙwayoyin tumo daga girma. Immunotherapy tare da kwayoyin cuta na monoclonal, kamar pembrolizumab, na iya taimaka wa garkuwar jiki ta kai hari ga kansar, kuma yana iya tsoma baki tare da ikon ƙwayoyin ƙari don girma da yaɗuwa. Bada talimogene laherparepvec da pembrolizumab na iya aiki mafi kyau wajen kula da marasa lafiya tare da melanoma ta hanyar rage tumor.

Wuri: Wurare 16

Dabrafenib, Trametinib, da Navitoclax a Kula da Marasa lafiya tare da BRAF Mutant Melanoma ko Tananan Tumor da ke Metarfafa ko Ba za a Iya Cire su ta Tiyata

Wannan gwajin na I / II yana nazarin illolin illa da mafi kyawun kwayar dabrafenib, trametinib, da navitoclax da kuma ganin yadda suke aiki cikin kula da marasa lafiya da cutar BRAF meantoma melanoma ko ciwace-ciwacen da suka bazu zuwa wasu sassan jiki ko ba za a iya cire su ba ta hanyar tiyata. Dabrafenib, trametinib, da navitoclax na iya dakatar da ci gaban ƙwayoyin tumo ta hana wasu enzymes da ake buƙata don ci gaban kwayar halitta.

Wuri: Wurare 24

Nazarin Avelumab A Haɗuwa Tare da Sauran Magungunan Imwayar Ciwon Cutar Ciwon Cutar Ci Gaban Raunin Rauni (JAVELIN Medley)

Wannan karatun kashi-1 ne na 2-ingantawa don kimanta aminci, kimiyyar magani, magani, da kuma aikin antitumor na farko na avelumab (MSB0010718C) tare da sauran maganin rigakafin cutar kansa a marasa lafiya tare da ci gaban gida ko ciwan ciwukwace. Babban manufar ita ce a tantance aminci da alamun farko na inganci na nau'ikan haɗuwa da avelumab tare da sauran magungunan rigakafin ciwon daji, da inganta ƙoshin maganin kamar yadda ya dace, a cikin jerin jerin alamomi.

Wuri: Wurare 12

Nazarin Immuno-therapy Nazarin don Tantance Tsaro, Haƙuri da Ingancin Anti-LAG-3 Tare da Ba tare da Anti-PD-1 ba a cikin Kula da Ciwan Tumurrai

Dalilin binciken shi ne a tantance aminci, jurewa da tasirin maganin gwaji na BMS-986016 wanda aka gudanar shi kadai kuma a hade da nivolumab a cikin marasa lafiya masu dauke da kumburi wadanda suka yadu kuma / ko ba za'a iya cire su ta hanyar tiyata ba. Wadannan nau'ikan ciwace-ciwacen an haɗa su a cikin wannan binciken: cerananan Lwayar Cutar Hanta (NSCLC), ciwon daji na ciki, cututtukan hanta na hanta, ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar cuta, da ƙwayar melanoma, da ba a taɓa kasancewa ba bi da tare da immunotherapy. NSCLC da melanoma waɗanda AKA taɓa magance su da rigakafin rigakafi.

Wuri: Wurare 12

Tsaro, Haƙuri da Nazarin PK na DCC-2618 a cikin Marasa lafiya Tare da Ciwon Cutar Gaggawa

Wannan na 1 ne na zamani, mai lakabin buɗaɗɗe, na farko-cikin mutum (FIH) nazarin haɓakar haɓaka wanda aka tsara don kimanta aminci, jurewa, ilimin kimiyyar magani (PK), pharmacodynamics (PD) da aikin rigakafin farko na DCC-2618, ana gudanar da shi da baki (PO), a cikin tsofaffin marasa lafiya da cututtukan ci gaba. Nazarin ya kunshi sassa 2, lokaci mai kara kuzari da fadada lokaci.

Wuri: Wurare 12

Nazarin NKTR-214 wanda aka Haɗa tare da Nivolumab vs Nivolumab Kadai a cikin Mahalarta Tare da Ciwon da ba a Magance shi ba ko Melanoma

Dalilin binciken shi ne a gwada inganci (yadda kwayar take aiki), aminci, da jure maganin binciken da ake kira NKTR-214, lokacin da aka hada shi da nivolumab da nivolumab aka ba shi kadai a cikin mahalarta tare da cutar daji ta melanoma da ba a kula da ita ba an kasa cire shi ta hanyar tiyata ko kuma ya yadu

Wuri: wurare 10

Nazarin Relatlimab Plus Nivolumab da Nivolumab Kadai a cikin Mahalarta Tare da Ci gaban Melanoma

Dalilin wannan binciken shine don tantance ko nivolumab a hade tare da relatlimab yafi tasiri fiye da nivolumab da kanta wajen kula da rashin lafiyar melanoma ko melanoma wanda ya yadu

Wuri: wurare 13

Pembrolizumab da Ipilimumab a Kula da Marasa lafiya tare da Ciwon Melanoma na baya

Wannan gwajin na lokaci na II yana nazarin yadda pembrolizumab da ipilimumab ke aiki cikin kulawa da marasa lafiya da melanoma da aka kula da ita a baya wanda ya bazu zuwa wasu sassan jiki. Immunotherapy tare da kwayoyin cuta na monoclonal, kamar pembrolizumab da ipilimumab, na iya taimakawa tsarin garkuwar jiki ya kai hari kansar, kuma yana iya tsoma baki tare da ikon ƙwayoyin ƙwayoyin cuta don girma da yaɗuwa.

Wuri: wurare 10

Nazarin Clinical na CMP-001 a cikin Haɗuwa Tare da Pembrolizumab ko azaman Monotherapy

Za a gudanar da wannan binciken a sassa biyu: Za a gudanar da Sashe na 1 ta amfani da Tsarin Kashe Kashi da Fadada. Sashe na Kashi na 1 Kashe Kashi na wannan binciken zai gano amintacce kuma mai juriya don a ci gaba da kimanta shi a cikin Sashe na Exparfafa Partarin Kashi na 1. Sashe na 2 na binciken za a gudanar da shi a layi daya tare da Sashe na 1 na Expasa Fadada kuma zai kimanta aminci da ingancin CMP-001 lokacin da aka gudanar azaman monotherapy.

Wuri: Wurare 12

Lokaci na 1b / 2 Gwajin Lenvatinib (E7080) Parin Pembrolizumab a cikin Batutuwa Tare da Zaɓaɓɓun uman Tumor

This is an open-label Phase 1b / 2 trial of lenvatinib (E7080) plus pembrolizumab in participants with selected solid tumors. Phase 1b will determine and confirm the maximum tolerated dose (MTD) for lenvatinib in combination with 200 milligrams (mg) (intravenous [IV], every 3 weeks [Q3W]) pembrolizumab in participants with selected solid tumors (i.e. non-small cell lung cancer, renal cell carcinoma, endometrial carcinoma, urothelial carcinoma, squamous cell carcinoma of the head and neck, or melanoma). Phase 2 (Expansion) will evaluate the safety and efficacy of the combination in 6 cohorts at the MTD from Phase 1b (lenvatinib 20 mg / day orally + pembrolizumab 200 mg Q3W, IV).

Location: 10 locations

Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma

Mai yiwuwa, nazarin cibiyoyin sadarwa da yawa na kimanta maganin kwayar halitta (ACT) ta hanyar jigilar LN-144 (autologous TIL) wanda ke biye da interleukin 2 (IL-2) bayan tsarin ba da tallafi na ba tare da tsari ba (NMA LD).

Wuri: wurare 13

1 2 3 ... 11 Na gaba>